Cargando…

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC

Effective treatments for recurrent/metastatic human papillomavirus-positive (HPV+) head and neck squamous cell cancer (HNSCC) are limited. To aid treatment development, we characterized a novel murine model of recurrent/metastatic HPV+ HNSCC. Further analysis of the parental tumor cell line and its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coppock, Joseph D., Vermeer, Paola D., Vermeer, Daniel W., Lee, Kimberly M., Miskimins, W. Keith, Spanos, William C., Lee, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029697/ https://www.ncbi.nlm.nih.gov/pubmed/27015118 http://dx.doi.org/10.18632/oncotarget.8286

Ejemplares similares

β(2)-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC
por: Lucido, Christopher T., et al.
Publicado: (2018)

Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC
por: Lucido, Christopher T., et al.
Publicado: (2018)

Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis
por: Vermeer, Daniel W., et al.
Publicado: (2016)

mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
por: Coppock, Joseph D., et al.
Publicado: (2016)

A Non-oncogenic HPV 16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors
por: Wieking, Bryant G., et al.
Publicado: (2012)

HPV+ cancer cell lactate production attenuates immune response during treatment: lactate production inhibition leads to improved long-term cures
por: Zhuang, Cathy, et al.
Publicado: (2012)

CD137 Enhancement of HPV Positive Head and Neck Squamous Cell Carcinoma Tumor Clearance
por: Lucido, Christopher T., et al.
Publicado: (2014)

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines
por: Subtil, Florentine S. B., et al.
Publicado: (2022)

The Impact of YRNAs on HNSCC and HPV Infection
por: Guglas, Kacper, et al.
Publicado: (2023)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate‐risk HPV‐negative HNSCC
por: Tasoulas, Jason, et al.
Publicado: (2021)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
por: Beelen, Karin, et al.
Publicado: (2014)

Biological Aspects of mTOR in Leukemia
por: Mirabilii, Simone, et al.
Publicado: (2018)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Callejas-Valera, Juan L., et al.
Publicado: (2022)

Role of mTOR Complexes in Neurogenesis
por: LiCausi, Francesca, et al.
Publicado: (2018)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Roles of mTOR Signaling in Brain Development
por: Lee, Da Yong
Publicado: (2015)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Targeting the mTOR pathway in Chromophobe Kidney Cancer
por: Shuch, Brian, et al.
Publicado: (2012)

SYK Regulates mTOR Signaling in AML
por: Carnevale, Julia, et al.
Publicado: (2013)

Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition
por: Klapproth, Erik, et al.
Publicado: (2018)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
por: Mateo, F, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vr74vmokgr54riuht5vvitjcg7